Clinical trials: Gingival Squamous Cell Carcinoma
Cancer, Solid Malignant Tumors
High-Resolution PET-CT Imaging for Surgical Margin Visualization
Imaging will be exploratory and be used intraoperatively. There have been no discovered risks associated with the device to be used in this study, and none are anticipated given the diagnostic and non-invasive, 'ex vivo' nature…
- Conditions
- Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC
- Trial name
- NCT06915454
- Testing
- Intra-op PET/CT Specimen Scanner
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer.
- Conditions
- Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma
- Trial name
- NCT04333537
- Testing
- Chest Radiography, Computed Tomography, Fludeoxyglucose F-18
- Where
- 107 sites in United States, Canada
- Volunteers
- 686 people
- Sponsor
- NRG Oncology
HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
This study is exploring the use of Panitumumab in Head and Neck Cancer. Panitumumab is an approved drug named Vectibix and is used as an anti-cancer agent in other cancers such as colorectal cancer.
- Conditions
- HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma
- Trial name
- NCT06819228
- Testing
- Panitumumab IRDye 800
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Oral Leukoplakia, Oral Leukoplakia of Tongue
Prediction of Malignant Transformation of Oral Leukoplakia Using a MAGE-A-based Immunoscore
Oral squamous cell carcinomas (OSCC) is among the most common malignancies worldwide. Early detection and prevention of OSCC is thought to have the highest potential to reduce morbidity and mortality.
- Conditions
- Oral Leukoplakia, Oral Leukoplakia of Tongue, Oral Leukoplakia of Gingiva, Oral Lichen Planus
- Trial name
- PREDICT-OLP (NCT03975322)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Upper Gingival Squamous Cell Carcinoma
Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms
Hypothesis: Cetuximab, an anti-EGFR antibody, is used with radiotherapy in the treatment of locally advanced and inoperable upper aerodigestive tract cancers.
- Trial name
- FCR-VADS (NCT01827956)
- Testing
- Cetuximab
- Where
- France
- Volunteers
- 121 people
- Sponsor
- Institut Bergonié
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
The study is an open-label phase I/II clinical trial. The study will enroll patients to receive neoadjuvant SBRT plus 1 or 2 doses of neoadjuvant pembrolizumab with concurrent ficerafusp alfa (4 doses) prior to definitive…
- Trial name
- NCT07552558
- Testing
- Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Washington University School of Medicine